Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Precigen, Inc., a wholly owned subsidiary of Intrexon Corporation (NYSE: XON), a leader in synthetic biology.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
FCX-007 for treatment of recessive dystrophic epidermolysis bullosa (RDEB)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):